Cargando…

Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin

Detalles Bibliográficos
Autor principal:	Kim, Kyung-Ah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2011
Materias:	The Korean Journal of Hepatology Elsewhere
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304624/ http://dx.doi.org/10.3350/kjhep.2011.17.1.84

Ejemplares similares

Role of vitamin D in chronic hepatitis C
por: Kim, Tae Yeob
Publicado: (2011)

Growing attention to an old marker, hepatitis B surface antigen, in the natural history of chronic hepatitis B
por: Jang, Jeong Won
Publicado: (2010)

The effect of sorafenib on hepatic stellate cells: implication of its effect on tumor microenvironment
por: Lee, Jung Il
Publicado: (2010)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

The use of vaptan in hyponatremic patients with liver cirrhosis
por: Choe, Won Hyeok
Publicado: (2011)

Body iron, serum ferritin, and nonalcoholic fatty liver disease
por: Shim, Jae-Jun
Publicado: (2012)

Cell-type specific functions of epidermal growth factor receptor are involved in development of hepatocellular carcinoma
por: Timchenko, Nikolai A
Publicado: (2015)

Bis‐choline Tetrathiomolybdate as Old Drug in a New Design for Wilson’s Disease: Good for Brain and Liver?
por: Stremmel, Wolfgang
Publicado: (2018)

Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
por: Sinha, Rohit A., et al.
Publicado: (2020)

Gut Microbes Take It to the Next Level? First Insights Into Farnesoid X Receptor Agonists of Microbial Origin
por: Lenicek, Martin, et al.
Publicado: (2020)

Long‐Term Perfusion of the Liver Outside the Body: Warming Up for Ex Vivo Therapies?
por: Schurink, Ivo J., et al.
Publicado: (2020)

Bile Duct Repair in Human Liver Grafts: Effective Cholangiocyte Organoid Engraftment and Plasticity
por: van der Laan, Luc J.W., et al.
Publicado: (2021)

Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C
por: Masaki, Naohiko, et al.
Publicado: (2014)

Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin
por: Choi, Sang Bun, et al.
Publicado: (2011)

Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues
por: Fan, Rong, et al.
Publicado: (2016)

Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study
por: Naing, Cho, et al.
Publicado: (2015)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

PNPLA3 gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis
por: Dunn, Winston, et al.
Publicado: (2019)

Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis
por: Zhang, Bing, et al.
Publicado: (2015)

Sustained Virologic Response to Peginterferon α-2a and Ribavirin in 335 Patients with Chronic Hepatitis C: A Tertiary Care Center Experience
por: Al Ashgar, Hamad, et al.
Publicado: (2008)

Noninvasive diagnosis of hepatocellular carcinoma
por: Kim, Byung Seok
Publicado: (2012)

Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C
por: Kwon, Jung Hyun, et al.
Publicado: (2009)

Increased Baseline Proinflammatory Cytokine Production in Chronic Hepatitis C Patients with Rapid Virological Response to Peginterferon Plus Ribavirin
por: Par, Gabriella, et al.
Publicado: (2013)

In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
por: Todt, Daniel, et al.
Publicado: (2016)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
por: Jung, Young Kul, et al.
Publicado: (2013)

Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis
por: Yee, Brittany E, et al.
Publicado: (2015)

Prediction of Treatment Week Eight Response & Sustained Virologic Response in Patients Treated with Boceprevir Plus Peginterferon Alfa and Ribavirin
por: Thompson, Alex, et al.
Publicado: (2014)

Durability of Sustained Virologic Response in Chronic Hepatitis C
por: Uyanikoglu, Ahmet, et al.
Publicado: (2013)

Low Rates of Sustained Virologic Response with Peginterferon Plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV Infected Patients in Rio de Janeiro, Brazil
por: Barcaui, Halime Silva, et al.
Publicado: (2013)

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy
por: Labarga, P, et al.
Publicado: (2010)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin
por: Nakayama, Masahiko, et al.
Publicado: (2015)

Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy
por: Nakamoto, Shingo, et al.
Publicado: (2017)

High Rate of Virological Response to Peginterferon α-2a–Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C
por: Alavi Moghaddam, Mostafa, et al.
Publicado: (2012)

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
por: Miyamura, Tatsuo, et al.
Publicado: (2012)

Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin
por: Yu, Ming-Lung, et al.
Publicado: (2012)

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
por: Silva, Giovanni Faria, et al.
Publicado: (2013)

Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis
por: Peng, Qin, et al.
Publicado: (2016)

The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
por: Han, Sung Yong, et al.
Publicado: (2021)

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
por: Jeong, Seok Hoo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3sb5a7c42jg9b2u8olse7ng8to